229 related articles for article (PubMed ID: 28571593)
1. Structure, signaling and the drug discovery of the Ras oncogene protein.
Han CW; Jeong MS; Jang SB
BMB Rep; 2017 Jul; 50(7):355-360. PubMed ID: 28571593
[TBL] [Abstract][Full Text] [Related]
2. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
3. Current status of the development of Ras inhibitors.
Shima F; Matsumoto S; Yoshikawa Y; Kawamura T; Isa M; Kataoka T
J Biochem; 2015 Aug; 158(2):91-9. PubMed ID: 26100833
[TBL] [Abstract][Full Text] [Related]
4. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
5. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
6. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
[TBL] [Abstract][Full Text] [Related]
7. Drugging all RAS isoforms with one pocket.
Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
[TBL] [Abstract][Full Text] [Related]
8. New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics.
Esposito D; Stephen AG; Turbyville TJ; Holderfield M
Semin Cancer Biol; 2019 Feb; 54():174-182. PubMed ID: 29432816
[TBL] [Abstract][Full Text] [Related]
9. Biology, pathology, and therapeutic targeting of RAS.
Rhett JM; Khan I; O'Bryan JP
Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
[TBL] [Abstract][Full Text] [Related]
10. Ras inhibition via direct Ras binding--is there a path forward?
Wang W; Fang G; Rudolph J
Bioorg Med Chem Lett; 2012 Sep; 22(18):5766-76. PubMed ID: 22902659
[TBL] [Abstract][Full Text] [Related]
11. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
12. Blocking Ras inhibition as an antitumor strategy.
Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
[TBL] [Abstract][Full Text] [Related]
13. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
14. Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith R; O'Bryan JP
Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
[TBL] [Abstract][Full Text] [Related]
15. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways.
Nussinov R; Tsai CJ; Mattos C
Trends Mol Med; 2013 Nov; 19(11):695-704. PubMed ID: 23953481
[TBL] [Abstract][Full Text] [Related]
16. How to make an undruggable enzyme druggable: lessons from ras proteins.
Sayyed-Ahmad A; Gorfe AA
Adv Protein Chem Struct Biol; 2020; 122():181-202. PubMed ID: 32951811
[TBL] [Abstract][Full Text] [Related]
17. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
18. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
19. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.
Erickson KE; Rukhlenko OS; Posner RG; Hlavacek WS; Kholodenko BN
Semin Cancer Biol; 2019 Feb; 54():162-173. PubMed ID: 29518522
[TBL] [Abstract][Full Text] [Related]
20. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
